Aclaris Therapeutics (ACRS) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free ACRS Stock Alerts $0.99 -0.02 (-1.88%) (As of 09:31 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 6, 2024 | globenewswire.comAclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 31, 2024 | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 18.2% in MayMay 31, 2024 | marketbeat.comShort Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Drops By 18.2%Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 4,870,000 shares, a drop of 18.2% from the April 30th total of 5,950,000 shares. Based on an average trading volume of 899,100 shares, the days-to-cover ratio is presently 5.4 days.May 28, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Hold" from BrokeragesShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have earned a consensus rating of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to thMay 22, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Stock Passes Below Fifty Day Moving Average of $1.21Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Crosses Below 50 Day Moving Average of $1.21May 14, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 19.2% in AprilAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 5,950,000 shares, a growth of 19.2% from the April 15th total of 4,990,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 5.6 days.May 11, 2024 | marketbeat.comMonaco Asset Management SAM Invests $1.03 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Monaco Asset Management SAM bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 979,399 shares of the biotechnology company's stock, valued at approximately $1,028,000. Monaco AssetMay 10, 2024 | finance.yahoo.comEarnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their EstimatesMay 10, 2024 | marketbeat.comLeerink Partnrs Equities Analysts Raise Earnings Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at Leerink Partnrs boosted their Q2 2024 earnings per share estimates for Aclaris Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now anticipates that the biotMay 8, 2024 | finance.yahoo.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | businesswire.comAmerican Clinical Research Services Announces Strategic Acquisition of ElixiaMay 8, 2024 | finance.yahoo.comAclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 7, 2024 | msn.comCrocs (CROX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | sfgate.comAclaris: Q1 Earnings SnapshotMay 7, 2024 | globenewswire.comAclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 7, 2024 | markets.businessinsider.comHere's what to expect from Aclaris Therapeutics's earnings reportMay 1, 2024 | marketbeat.comAclaris Therapeutics (ACRS) to Release Earnings on TuesdayAclaris Therapeutics (NASDAQ:ACRS) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=592103)April 30, 2024 | finance.yahoo.comAclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate UpdateApril 27, 2024 | money.usnews.comAclaris Therapeutics IncApril 24, 2024 | marketbeat.comBML Capital Management LLC Invests $686,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)BML Capital Management LLC bought a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 653,107 shares of the bioApril 11, 2024 | finance.yahoo.comFavourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired StockMarch 25, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday.March 16, 2024 | finance.yahoo.comACRS Apr 2024 1.000 callMarch 8, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Lowered to "Sell" at StockNews.comStockNews.com lowered Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday.March 7, 2024 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for shares of Aclaris Therapeutics in a research note issued to investors on Monday, March 4th. HC Wainwright analyst R. Selvaraju now expects that the bioMarch 6, 2024 | marketbeat.comHC Wainwright Weighs in on Aclaris Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Research analysts at HC Wainwright issued their FY2025 earnings per share estimates for Aclaris Therapeutics in a research note issued on Monday, March 4th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company willMarch 4, 2024 | markets.businessinsider.comAclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline PotentialMarch 4, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest UpdateAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 5,830,000 shares, a drop of 7.9% from the January 31st total of 6,330,000 shares. Based on an average trading volume of 2,480,000 shares, the days-to-cover ratio is presently 2.4 days.March 1, 2024 | markets.businessinsider.comAclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical SetbacksMarch 1, 2024 | marketbeat.comAclaris Therapeutics, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.31) Per Share (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at William Blair raised their Q1 2024 earnings estimates for Aclaris Therapeutics in a note issued to investors on Tuesday, February 27th. William Blair analyst T. Lugo now expects that the biotechnology company will post earningsMarch 1, 2024 | marketbeat.comDeutsche Bank AG Sells 932,311 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Deutsche Bank AG decreased its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 85.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 154,309 shares of the biotechnology compFebruary 29, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Aclaris Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Research analysts at William Blair issued their Q1 2025 EPS estimates for shares of Aclaris Therapeutics in a research note issued to investors on Tuesday, February 27th. William Blair analyst T. Lugo anticipates that the biotechnology compFebruary 29, 2024 | finance.yahoo.comAnalysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%February 27, 2024 | msn.comAclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55MFebruary 27, 2024 | globenewswire.comAclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateFebruary 20, 2024 | finance.yahoo.comPacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseFebruary 20, 2024 | marketbeat.comAclaris Therapeutics (ACRS) Scheduled to Post Earnings on WednesdayAclaris Therapeutics (NASDAQ:ACRS) will be releasing earnings on Wednesday, February 21, Yahoo Finance reports.February 15, 2024 | finance.yahoo.comWill Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should KnowFebruary 7, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) to Post FY2023 Earnings of ($1.63) Per Share, Leerink Partnrs ForecastsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Leerink Partnrs increased their FY2023 earnings per share estimates for Aclaris Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biotechnology company will post earnings oFebruary 6, 2024 | msn.comAclaris Therapeutics Executive Team Undergoes Major ChangesFebruary 6, 2024 | marketbeat.comAnalysts Set Expectations for Aclaris Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Aclaris Therapeutics in a report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the biotechnology companyJanuary 22, 2024 | msn.comHW Wainwright cuts Aclaris to neutral, cites underwhelming study dataJanuary 16, 2024 | msn.comWhy Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?January 16, 2024 | bizjournals.comAclaris moves on from CEO and begins strategic review following recent setbacksJanuary 11, 2024 | msn.comBTIG Downgrades Aclaris Therapeutics (ACRS)January 11, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Aclaris TherapeuticsJanuary 11, 2024 | realmoney.thestreet.comJefferies gets more bearish on Aclaris Therapeutics, downgrades sharesJanuary 10, 2024 | msn.comAclaris downgraded at Jefferies despite mid-stage win for eczema therapyJanuary 10, 2024 | markets.businessinsider.comAnalyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data VariationsJanuary 10, 2024 | msn.comAclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. ACRS Media Mentions By Week ACRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼0.000.76▲Average Medical News Sentiment ACRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼12▲ACRS Articles Average Week Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XOMA News Today ADC Therapeutics News Today CorMedix News Today Mersana Therapeutics News Today Vanda Pharmaceuticals News Today Nature's Sunshine Products News Today Xeris Biopharma News Today Aquestive Therapeutics News Today Revance Therapeutics News Today ESSA Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored